Get started
Author

M. Shi

Comparison of Genome Screens for Two Independent Cohorts Provides Replication of Suggestive Linkage of Bone Mineral Density to 3p21 and 1p36
2003 · S.G. Wilson, P.W. Reed, et al. · The American Journal of Human Genetics · 132
PDF
A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).
2011 · E. Angevin, V. Grünwald, et al. · Journal of Clinical Oncology · 56
Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain
2019 · L.Q. Chow, F. Barlesi, et al. · Annals of Oncology · 43
Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells
2009 · P. Wei, M. Shi, et al. · Diabetologia · 43
PDF
A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.
2011 · F. Andre, T. D. Bachelot, et al. · Journal of Clinical Oncology · 32
A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results.
2010 · E. Angevin, C. Lin, et al. · Journal of Clinical Oncology · 23
TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study
2009 · E. Angevin, J. A. Lopez, et al. · Journal of Clinical Oncology · 22
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
2012 · A Giatromanolaki, M I Koukourakis, et al. · British Journal of Cancer · 21
PDF
Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib)
2012 · P M Wilson, D Yang, et al. · The Pharmacogenomics Journal · 17
Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study
2019 · F. Barlesi, D.-W. Kim, et al. · Annals of Oncology · 11
A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3.
2011 · M. I. Milowsky, G. L. Carlson, et al. · Journal of Clinical Oncology · 10
Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor (TKI) in patients enrolled in CONFIRM1 and CONFIRM2
2008 · P. M. Wilson, D. Yang, et al. · Journal of Clinical Oncology · 10
Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer.
2010 · F. Andre, J. Baselga, et al. · Journal of Clinical Oncology · 8
511MO A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced non-small cell lung cancer (NSCLC)
2023 · J. Feng, M. Shi, et al. · Annals of Oncology · 7
Modelling TKI258 exposure and biomarker response in support of phase I dosing schedule finding
2008 · X. Wang, J. Saro, et al. · Journal of Clinical Oncology · 7
Effect of TKI258 on plasma biomarkers and pharmcokinetics in patients with advanced melanoma
2009 · M. Shi, K. B. Kim, et al. · Journal of Clinical Oncology · 6
The pharmacodynamic effect of TKI258 on plasma biomarkers of angiogenesis in patients with AML and advanced melanoma
2008 · M. M. Shi, M. Motwani, et al. · Journal of Clinical Oncology · 6
Tumor VEGFA gene expression is associated with serum lactate dehydrogenase (LDH) levels and intratumoral mRNA expression of genes involved in glycolysis in patients with metastatic colorectal cancer (mCRC)
2006 · M. Azuma, M. M. Shi, et al. · Journal of Clinical Oncology · 5
Intratumoral lactate dehydrogenase 5 (LDH5) protein expression is associated with expression of angiogenesis markers and hypoxia in patients with colorectal cancer (CRC)
2007 · M. I. Koukourakis, A. Giatromanolaki, et al. · Journal of Clinical Oncology · 4
First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
2019 · D.S. Tan, S. Geater, et al. · Annals of Oncology · 3
UPDATED RESULTS FROM A PHASE 1B STUDY OF AMDIZALISIB, A NOVEL INHIBITOR OF PHOSPHOINOSITIDE 3‐KINASE‐DELTA (PI3Kδ), IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA
2023 · J. Cao, D. Ji, et al. · Hematological Oncology · 2
OA14.04: RC148 (ABBV-1480, PD-1/VEGF Bispecific Antibody) Plus Chemotherapy in First-Line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2026 · L. Zhang, Y. Zhao, et al. · Journal of Thoracic Oncology
EP12.21: Patients’and Physicians’perception on "Clinical Cure" in Locally Advanced or Metastatic NSCLC: A Nationwide Survey in China
2026 · W. Li, X. Dong, et al. · Journal of Thoracic Oncology
P2.379: A Phase 3, Randomized, Double-Blind Trial of RC148 (ABBV-1480) Plus Chemotherapy in First-Line Squamous Non-Small-Cell Lung Cancer
2026 · L. Zhang, Y. Fan, et al. · Journal of Thoracic Oncology
P2.329: QL1706 Plus Pm-Pac and Platinum in the Treatment of Stage III Unresectable NSCLC: Preliminary Results From Dynamic-Duo Study
2026 · M. Shi, T. Lv, et al. · Journal of Thoracic Oncology
Works count: 30
Citation count: 468
H-index: 10
I10-index: 12
Year
Topic
Type